BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jerums G, Allen TJ, Campbell DJ, Cooper ME, Gilbert RE, Hammond JJ, Raffaele J, Tsalamandris C. Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. Am J Kidney Dis. 2001;37:890-899. [PMID: 11325669 DOI: 10.1016/s0272-6386(05)80003-4] [Cited by in Crossref: 53] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Huang R, Feng Y, Wang Y, Qin X, Melgiri ND, Sun Y, Li X. Comparative Efficacy and Safety of Antihypertensive Agents for Adult Diabetic Patients with Microalbuminuric Kidney Disease: A Network Meta-Analysis. PLoS One 2017;12:e0168582. [PMID: 28045910 DOI: 10.1371/journal.pone.0168582] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 McFarlane PA, Tobe SW, Culleton B. Improving outcomes in diabetes and chronic kidney disease: the basis for Canadian guidelines. Can J Cardiol 2007;23:585-90. [PMID: 17534468 DOI: 10.1016/s0828-282x(07)70806-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
3 Omae K, Ogawa T, Nitta K. Influence of T-calcium channel blocker treatment on deterioration of renal function in chronic kidney disease. Heart Vessels 2009;24:301-7. [PMID: 19626404 DOI: 10.1007/s00380-008-1125-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
4 Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev 2006;:CD006257. [PMID: 17054288 DOI: 10.1002/14651858.CD006257] [Cited by in Crossref: 72] [Cited by in F6Publishing: 44] [Article Influence: 4.8] [Reference Citation Analysis]
5 Sourris KC, Harcourt BE, Penfold SA, Yap FY, Morley AL, Morgan PE, Davies MJ, Baker ST, Jerums G, Forbes JM. Modulation of the cellular expression of circulating advanced glycation end-product receptors in type 2 diabetic nephropathy. Exp Diabetes Res 2010;2010:974681. [PMID: 21318189 DOI: 10.1155/2010/974681] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
6 Thomas MC, Atkins RC. Blood pressure lowering for the prevention and treatment of diabetic kidney disease. Drugs 2006;66:2213-34. [PMID: 17137404 DOI: 10.2165/00003495-200666170-00005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
7 Wenzel RR. Renal protection in hypertensive patients: selection of antihypertensive therapy. Drugs 2005;65 Suppl 2:29-39. [PMID: 16398060 DOI: 10.2165/00003495-200565002-00005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
8 Liang J, Lan J, Tang Q, Ling W, Li M. Short- and long-term treatment with angiotensin-converting enzyme inhibitors or calcium channel blockers for the prevention of diabetic nephropathy progression: A meta-analysis. Exp Ther Med 2021;21:14. [PMID: 33235623 DOI: 10.3892/etm.2020.9446] [Reference Citation Analysis]
9 Zelmanovitz T, Gerchman F, Balthazar AP, Thomazelli FC, Matos JD, Canani LH. Diabetic nephropathy. Diabetol Metab Syndr 2009;1:10. [PMID: 19825147 DOI: 10.1186/1758-5996-1-10] [Cited by in Crossref: 68] [Cited by in F6Publishing: 61] [Article Influence: 5.7] [Reference Citation Analysis]
10 Martins D, Norris K. Combating diabetic nephropathy with drug therapy. Curr Diab Rep 2001;1:148-56. [PMID: 12643111 DOI: 10.1007/s11892-001-0027-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]